主要围绕中草药活性成分筛选及作用机制探究、新型中兽药制剂研发、微生物与宿主互作及机制、天然免疫调控等方向展开。主持、参与中国博士后基金、北京市自然科学基金重大专项、国家重点研发计划重点专项等多个国家级及省部级项目。近五年以第一作者发表SCI论文8篇（包括2篇《Cell》子刊《Cell Reports》）。以第二完成人身份申请专利7项（均已授权）。

2015.09-2020.07  中国农业大学，动物科学，博士

2018.06-2019.01  美国北卡州立大学，生命科学，访问学者

2011.09-2015.07  中国农业大学，水产养殖学，学士

2020.10-2024.05  清华大学，药学院，博士后/助理研究员

2024.06-至今     中国农业大学，动物医学院，副教授

中兽药学，天然免疫，小分子药物设计及开发、微生物与宿主互作及机制

2023年    清华大学-北京大学生命科学联合中心（CLS）优秀博士后

2021年    清华大学-北京大学生命科学联合中心（CLS）优秀博士后

2020年    北京市优秀毕业生、中国农业大学校级优秀毕业生、中国农业大学动物科技学院优秀毕业论文

2019年    博士研究生国家奖学金、动物科技学院“院长奖学金”

2018年    中国畜牧兽医学会“优秀论文奖”

1. 中国博士后科学基金：细菌中辅助cGAMP等第二信使激活STING通路的效应分子的筛选及其生物学活性和机制研究，2021.11-2024.05，主持/结题

2. 北京市自然科学基金重大专项：cGAS-STING信号通路在HIV合并结合分歧杆菌感染中的作用机制及转化研究，2022.10-2026.10，参与

3. 国家重点研发计划重点专项：畜禽养殖绿色安全饲料饲养新技术研发，2018.06-2021.06，参与

4. 北京市重点研发计划：畜禽绿色无抗养殖技术研究与示范，2020.08-2022.08，参与

1. Lulu Zhang, Xubiao Wei, Zhimeng Wang, Peiyuan Liu, Yanfei Hou, Yifang Xu, Huili Su, Matthew D. Koci, Hang Yin, and Conggang Zhang. NF-κB activation enhances STING signaling via altering microtubule-mediated STING trafficking. Cell Reports 42 (2023) 112185. Doi: 10.1016 /j. celrep.2023.112185. (Highly cited paper)

2. Xubiao Wei^#, Lulu Zhang^#, Yinlong Yang, Yanfei Hou, Yifang Xu, Zhimeng Wang, Huili Su, Fangping Han, Jing Han, Peiyuan Liu, Shuiqing Hu, Matthew D. Koci, Xuxu Sun, and Conggang Zhang. LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity. Cell Reports 39 (9) (2022) 110880. Doi: 10.1016/j. celrep.2022.110880., (Co-first author);

3. Lulu Zhang, Xubiao Wei, Rijun Zhang, Matthew Koci, Dayong Si, Baseer Ahmad, Henan Guo and Yanfei Hou, C-terminal Amination of a Cationic Anti-inflammatory Peptide Improves Bioavailability and Inhibitory Activity against LPS-induced Inflammation. Frontiers in Immunology (2021) 11:618312. Doi: 10.3389/fimmu.2020.618312;

4. Lulu Zhang, Xubiao Wei, Rijun Zhang, Jim N. Petitte, Dayong Si, Zhongxuan Li, Junhao Cheng and Mengsi Du. Design and Development of a Novel Peptide for Treating Intestinal Inflammation. Frontiers in Immunology (2019) Doi: 10.3389/fimmu.2019.01841;

5. Xubiao Wei^#, Lulu Zhang^#, Rijun Zhang, Rujuan Wu, James N. Petitte, Yanfei Hou, Dayong Si, Baseer Ahmad, Henan Guo, Manyi Zhang, Qiang Cheng and Yucui Tong. Targeting the TLR2 receptor with a novel thymopentin-derived peptide modulates immune responses. Frontiers in Immunology (2021) doi: 10.3389/fimmu.2021.620494 (Co-first author);

6. Lulu Zhang, Xubiao Wei, Rijun Zhang, Paul E. Mozdziak, Dayong Si, Baseer Ahmad, Qiang Cheng and Yucui Tong. Design and immunological evaluation of a hybrid peptide as a potent TLR2 agonist by structure-based virtual screening. Frontiers in Cell and Developmental Biology Molecular Medicine (2021) 9:620370. doi: 10.3389/fcell.2021.620370;

7. Lulu Zhang, Xubiao Wei, Rijun Zhang, Dayong Si, James N. Petitte, Baseer Ahmad and Manyi Zhang. A Novel Peptide Ameliorates LPS-Induced Intestinal Inflammation and Mucosal Barrier Damage via Its Antioxidant and Antiendotoxin Effects. International Journal of Molecular Sciences (2019) 20(16). Epub 2019/08/25;

8. Lulu Zhang, Xubiao Wei, Rijun Zhang, Matthew Koci, Dayong Si, Baseer Ahmad, Junhao Cheng and Junyong Wang. Efficient Hybrid Peptide That Increases Immunomodulatory Activity Via the TLR4-Mediated Nuclear Factor-kappa B Signaling Pathway. International Journal of Molecular Sciences (2019) 20(24). Epub 2019/12/06;